Pharma's Cousin, Biotech, Is Showing Some Major Topping Signs
|
|
- Letitia Carroll
- 5 years ago
- Views:
Transcription
1 Pharma's Cousin, Biotech, Is Showing Some Major Topping Signs March 18, 2016 by Eric Bush of GaveKal Capital Yesterday, Jennifer asked is Valeant Pharmaceuticals the proverbial canary in the coal mine for the pharma industry? She came to the conclusion that the outlook for pharmaceutical stocks is certainly not as optimistic as it was six months ago. If the pharma s outlook is less optimistic than biotech s outlook is downright pessimistic. You may be asking haven t US biotech stocks already been under a lot of pressure? Absolutely. The average US biotech stock is down a substantial 23.8% over the past year. But before the contrarians out there start shuffling through the biotech bargain bin, remember that the average biotech stock is still 229% higher than it was four years ago (four stocks were excluded from this calculation due to lack of historic prices). So even though the one year returns imply that maybe the correction has overshot, when we look at these stocks from a four year perspective we see that most stocks are in the process of putting in major tops that could be the first sign that this is a multi-year drawdown period for biotech stocks. Let s take a look at the five largest holdings of the ishares Nasdaq Biotechnology ETF (ticker: IBB) as they account for 44.1% of the total ETF. Celgene has been in a topping formation since late 2014 and looks to have put in a significant amount of overhead bearish resistance. That is strike one. Strike two is that it has now broken the bullish highperformance support line for the first time (in a substantial way) in over four years. Strike three will be if (when) support gives way at line D. If D does give way, then the blue bullish support line may provide momentary support but we would expect Celgene to eventually crash through that as well. Page 1, 2018 Advisor Perspectives, Inc. All rights reserved.
2 Amgen has the best looking chart of these five stocks by far. Bullish support has still held. However, similar to the other charts, a good amount of overhead resistance is now in place. Amgen currently has one strike against it. However, if D gives way than Amgen will have strike two and three happen simultaneously as support from D and from the bullish support line will both have failed. Page 2, 2018 Advisor Perspectives, Inc. All rights reserved.
3 Biogen has two strikes against it. It has broken the bullish support line that had been in place since 2012 and has created a significant line of overhead resistance. If G gives way than we are probably looking at a 25-50% relative underperformance period ahead for Biogen. Page 3, 2018 Advisor Perspectives, Inc. All rights reserved.
4 Gilead Science has been in a topping formation since 2014 and looks to have put in a significant amount of bearish resistance. That is strike one. Strike two is that it has now broken the bullish highperformance support line for the first time in four years. Strike three will be if (when) support gives way at line D. F would then be the closest area of support. Page 4, 2018 Advisor Perspectives, Inc. All rights reserved.
5 Regeneron Pharmaceuticals probably has the worst looking chart of these five stocks. We think it is safe to say that Regeneron has just struck out and investors should get out of the batter s box. Strike one was putting in a lot of overhead resistance since early Strike two was falling through the bullish support line that had been in place since And strike three is that there doesn t seem to be any meaningful support until perhaps we get to H. This implies that there is about 30% relative performance downside, at a minimum, for Regeneron. The current situation Regeneron finds itself is the worst case scenario for the other four stocks we have mentioned. Page 5, 2018 Advisor Perspectives, Inc. All rights reserved.
6 The best case scenario for US biotech stocks is that support holds and these stocks end up staying in a prolong trading range. Stocks work off previous periods of excess either through time or price. Regeneron looks like it is already working off its incredible performance through price. We will see whether Regeneron is the model for other biotech stock performance in the near future or if it is the anomaly of the group. GaveKal Capital Page 6, 2018 Advisor Perspectives, Inc. All rights reserved.
7 Page 7, 2018 Advisor Perspectives, Inc. All rights reserved.
VANECK VECTORS BIOTECH ETF (BBH)
VANECK VECTORS BIOTECH ETF (BBH) $132.32 USD Risk: High Zacks ETF Rank 1 - Strong Buy Fund Type Issuer Benchmark Index Health Care ETFs VAN ECK MVIS US LISTED BIOTECH 25 INDEX BBH Sector Weights Date of
More informationRisk: N/A Zacks ETF Rank N/A - BIB Sector Weights. Price Chart
November 24, 2016 PROSHARES ULTRA NASDAQ BIOTECHNOLOGY (BIB) $45.89 Risk: N/A Zacks ETF Rank N/A - Fund Type Issuer Healthcare - Biotech PROFUNDS GROUP BIB Sector Weights Benchmark Index NASDAQ BIOTECHNOLOGY
More informationISHARES NASDAQ BIOTECHNOLOGY ETF (IBB)
ISHARES NASDAQ BIOTECHNOLOGY ETF (IBB) $109.44 USD Risk: High Zacks ETF Rank 2 - Buy Fund Type Issuer Benchmark Index Health Care ETFs BLACKROCK NASDAQ BIOTECHNOLOGY INDEX IBB Sector Weights Date of Inception
More informationISHARES NASDAQ BIOTECHNOLOGY ETF (IBB)
ISHARES NASDAQ BIOTECHNOLOGY ETF (IBB) $106.77 USD Risk: High Zacks ETF Rank 3 - Hold Fund Type Issuer Benchmark Index Health Care ETFs BLACKROCK NASDAQ BIOTECHNOLOGY INDEX IBB Sector Weights Date of Inception
More informationExploiting the Inefficiencies of Leveraged ETFs
Exploiting the Inefficiencies of Leveraged ETFs [Editor s Note: Here at WCI we try to keep things as simple as possible, most of the time. Not today though. Today we re going to be discussing leveraged
More informationTradespoon MetaStock Add-on
Tradespoon MetaStock Add-on An institutional-grade tool for the self-directed trader Overview MetaStock delivers powerful tools, powerful trades, and proprietary scanning, endless customization, comprehensive
More information27PercentWeekly. By Ryan Jones. Part II in the Series Start Small and Retire Early Trading Weekly Options
By Ryan Jones Part II in the Series Start Small and Retire Early Trading Weekly Options Important My 27% Option Strategy is one of the best option trading opportunities you will come across. When you see
More informationCIF Sector Recommendation Report (Fall 2012)
CIF Sector Recommendation Report (Fall 2012) Date: 11/29/12 Analyst: Khalid Surur Sector Healthcare Review Period: November 12-November 23rd Section (A) Sector Performance Review Copy/paste Sector Review
More informationPBE Invesco Dynamic Biotechnology & Genome ETF
Invesco Dynamic Biotechnology & Genome ETF ETF.com segment: Equity: U.S. Biotech Competing ETFs: IBB, XBI, FBT, BBC, CNCR Related ETF Channels: Biotech, Smart-Beta ETFs, U.S., Sectors, Healthcare, Biotechnology,
More informationIncome Opportunities for Summer with SPY ETF
Income Opportunities for Summer with SPY ETF June 2016 Gareth Ryan Founder & Managing Director Risk Disclaimer Options are leveraged products that involve risk and are not suitable for all investors. Before
More informationHow Fund Managers Are Positioned
How Fund Managers Are Positioned March 23, 2018 by Urban Carmel of The Fat Pitch Summary: Fund managers came into 2018 very bullish equities. Cash levels had fallen to the lowest level in 4 years. Allocations
More informationTrailing PE Forward PE Buy 28 Analysts. 1-Year Return: -4.4% 5-Year Return: -1.0%
GILEAD SCIENCES INC (-O) Last Close 69.20 (USD) Avg Daily Vol 7.1M 52-Week High 89.54 Trailing PE 57.7 Annual Div 2.28 ROE 6.7% LTG Forecast -5.0% 1-Mo -9.3% November 16 NASDAQ Exchange Market Cap 89.5B
More informationOPTIONS STRATEGY QUICK GUIDE
OPTIONS STRATEGY QUICK GUIDE OPTIONS STRATEGY QUICK GUIDE Trading options is a way for investors to take advantage of nearly any market condition. The strategies in this guide will let you trade, generate
More informationWeekly Market Summary
Weekly Market Summary April 24, 2016 by Urban Carmel of The Fat Pitch Summary: SPY made a new all-time high this week. The short and long term trend is higher. Despite a gain of 16% over the past 10 weeks,
More informationSycamore Market Analysis
Sycamore Market Analysis September 30, 2015 The third quarter came to an end with big gains for stocks. The rally did not quite reverse the effect of selling on Monday though with the S&P 500 still down
More informationWeekly Options Secrets Revealed: A Proven Options Trading Plan
Weekly Options Secrets Revealed: A Proven Options Trading Plan When talking about stock options there are many common questions that come up. Which strike price should I trade? Should I buy or sell the
More informationFBT First Trust NYSE Arca Biotechnology Index Fund
First Trust NYSE Arca Biotechnology Index Fund ETF.com segment: Equity: U.S. Biotech Competing ETFs: XBI, BBC, CNCR, BBP, IBB Related ETF Channels: North America, Biotech, U.S., Equal-Weighted, Smart-Beta
More informationCIF Sector Recommendation Report (Spring 2013)
Date: 4/1/2013 Analyst: Jacob Allen CIF Sector Recommendation Report (Spring 2013) Sector: Healthcare Review Period: 3/13/2013 3/26/2013 Section (A) Sector Performance Review Copy/paste Sector Review Spreadsheet
More informationHOW THE DEAD CAT BOUNCE STOCK TRADING PATTERN WORKS by Michael Swanson
HOW THE DEAD CAT BOUNCE STOCK TRADING PATTERN WORKS by Michael Swanson Hello my name is Michael Swanson and I m the author of Strategic Stock Trading and The Two Fold Formula, which is a book about the
More informationPLEASE SEE IMPORTANT LEGAL DISCLAIMER ON LAST PAGE
Today's Overview The S&P 500 ground sideways overnight into Wednesday and turned higher after the start of the U.S. session, rising to 1160 over the lunch hour. The Nasdaq 100 underperformed in the morning
More informationFranklin Biotechnology Discovery Fund A (acc) USD
Franklin Discovery Fund A (acc) USD Franklin Templeton Investment Funds Fund Manager Report Equity Product Details 1 Fund Assets $2,026,977,439.38 Fund Inception Date 03/04/2000 Number of Issuers 96 Bloomberg
More informationPortfolio Portfolio Constituents Benchmark. Equity Sector Breakdown Portfolio % Benchmark %
Morningstar Direct SM Print Date: 2/9/26 Page of /8/26 EUR Euribor Month EUR MSCI World EUR Equity Style Box Giant Large Mid Small Micro 6 29 Deep Value Core Value Blend Core Growth High Growth Portfolio
More informationNEXT EDGE BIOTECH BAROMETER CHARTBOOK
NEXT EDGE BIOTECH BAROMETER CHARTBOOK NEXT EDGE BIOTECH BAROMETER CHARTBOOK: OCTOBER 12 TH, 2018 With the recent sharp decline in global equity markets and Biotech companies, resulting in a 11% decline
More information2017 SUMMARY PROSPECTUS
AUGUST 1, 2017 2017 SUMMARY PROSPECTUS ishares Nasdaq Biotechnology ETF IBB NASDAQ Before you invest, you may want to review the Fund s prospectus, which contains more information about the Fund and its
More informationRabidly Risk Averse. July 13, 2016 by Richard Bernstein of Richard Bernstein Advisors
Rabidly Risk Averse July 13, 2016 by Richard Bernstein of Richard Bernstein Advisors 1999 was a very unique period. There was an overwhelming consensus that the new economy was a permanent investment theme
More informationMARKET REVIEW - DECEMBER
Defying Gravity Stocks continue to climb 'Wall of Worry'. December 1, 2009 ON THE EDGE MARKET REVIEW - DECEMBER 2009 Following a lackluster October, stocks showed marked improvement during November despite
More informationTrading Unusual Options Activity and Earnings
Trading Unusual Options Activity and Earnings Presented by James Ramelli Past performance is not indicative of future results. RISK DISCLAIMER Day trading, short term trading, options trading, and futures
More informationTax Loss Harvesting+ Tax Loss Harvesting+ is powered by Betterment, our custodial and technology partner.
Tax Loss Harvesting+ TM Tax Loss Harvesting+ is powered by Betterment, our custodial and technology partner. What is Tax Loss Harvesting (TLH)? TLH is a tax-saving strategy that uses investment losses
More informationHEALTH CARE SECTOR REPORT. Jiajun Wang Yuhao Wu Nick LiBassi
HEALTH CARE SECTOR REPORT Jiajun Wang Yuhao Wu Nick LiBassi AGENDA Overview Business Analysis Economic Analysis Financial Analysis Valuation Analysis Recommendation OVERVIEW THE SIZE OF HEALTH CARE SECTOR
More informationCIF Sector Recommendation Report (Spring 2013)
Date: 24 April 2013 Analyst: Garrett Lachney CIF Sector Recommendation Report (Spring 2013) Sector: Healthcare Review Period: 04/05-04/18 Section (A) Sector Performance Review Copy/paste Sector Review
More informationWeekly outlook for Mar
Weekly outlook for Mar. 26 30 2018 Summary The S&P500 index is expected to test February's low first and bounce from it before the Good Friday holiday. The end of the month and the end of the quarter may
More informationPension Fund May 2018
Pension Fund May 2018 Aviva Pension AXA Framlington Biotech AP This factsheet provides factual information only. The information shown should not be used in isolation for making buying and selling decisions.
More informationFund Managers Get Bullish
Fund Managers Get Bullish November 15, 2017 by Urban Carmel of The Fat Pitch Summary: Global equities have risen 18% so far in 2017 and yet, until this month, fund managers have held significant amounts
More informationNASDAQ OMX Advisory Insights Biotech
In an attempt to better understand the sell-off in the biotech sector over the past 2+ of months, the NASDAQ OMX Biotech Advisory Services team has compiled the following report. This report summarizes
More informationMethodology. Our team of analysts uses technical and chartist analysis to draw an opinion and make decisions. The preferred chartist elements are:
Methodology Technical analysis is at the heart of TRADING CENTRAL's expertise. Our methodology is proven. Our chartist and quantitative approach allows us to intervene on different investment horizons.
More informationBUZZ SOCIAL MEDIA INSIGHTS INDEX December 2016 Monthly Index Rebalance OUT
Z SOCIAL MEDIA INSIGHTS INDEX Investing just got social SUMMARY OF CHANGES IN OUT COMPANY ULTA Salon, Cosmetics & Fragrance, Inc. Home Depot Inc. Costco Wholesale Corp. Applied Materials Inc. Palo Alto
More informationThe Neutral Market Strategy
The Neutral Market Strategy GOAL To make a profit selling options in a sideways-moving market. SUMMARY Experts estimate that markets typically trend roughly 30% of the time. The remaining 70% of the time
More informationCash Cow Newsletter April
Cash Cow Newsletter April 16 2014 In this week s Cash Cow newsletter I would like to analyze the current state of the market and review strategies that can help protect us in high volatility environments.
More informationManaging stocks in long-term trading ranges 60% to 70% of all stocks exhibit trading range patterns even in a bull market.
Managing stocks in long-term trading ranges 60% to 70% of all stocks exhibit trading range patterns even in a bull market. Distribution of returns Normal vs. Fat Tails Theoretical distribution Observed
More informationCIF Sector Recommendation Report (Spring 2013)
Date: 2/19/13 Analyst: Joseph Brendel CIF Sector Recommendation Report (Spring 2013) Sector: Health Care (XLV) Review Period: February 1- February 14 Section (A) Sector Performance Review Copy/paste Sector
More informationBMO Nasdaq 100 Equity Hedged to CAD Index ETF (ZQQ) (the ETF )
ANNUAL MANAGEMENT REPORT OF FUND PERFORMANCE BMO Nasdaq 100 Equity Hedged to CAD Index ETF (ZQQ) (the ETF ) For the 12-month period ended December 31, 2017 (the Period ) Manager: BMO Asset Management Inc.
More informationPLEASE SEE IMPORTANT LEGAL DISCLAIMER ON LAST PAGE
Page 1 Page 3 Page 6 Page 7 Page 8 The Market: Choppiness Anticipated New Ideas: LQD, MSFT, BA Updates: JCP, AAPL, RVBD, XLI, JPM Today s Indicator Reader Feedback & Questions: SDS, XEC, SWY The Market
More information1 P a g e. Executive Summary
Executive Summary Based on this week s deduction of observable facts, we continue to favor the major a at SPX 1867, major b at SPX 2021 and major c down to SPX 1830-1850ies around October 9-12. How exactly
More informationWhat s the Canary in the Financial Coal Mine Saying?
What s the Canary in the Financial Coal Mine Saying? December 22, 2015 by Martin Pring of Pring Turner Capital Group Credit spreads, which measure the relationship between bonds of different credit ratings,
More informationFinance 527: Lecture 30, Options V2
Finance 527: Lecture 30, Options V2 [John Nofsinger]: This is the second video for options and so remember from last time a long position is-in the case of the call option-is the right to buy the underlying
More informationHEIKIN-ASHI TRENDS NEWSLETTER
HEIKIN-ASHI TRENDS NEWSLETTER INDEXES EQUITIES FOREX CRYPTOCURRENCIES #227 05.13.2018 EDUCOFIN 2013-2018. ALL RIGHTS RESERVED 25% DISCOUNT BE YOUR MASTER, A HEIKIN-ASHI MASTER. ORDER BOTH HEIKIN-ASHI TRADING
More informationPortfolio Volatility: Friend or Foe?
Volatility: Friend or Foe? The choice is yours if your financial goals are well defined. KEY TAKEAWAYS Set clear goals for your financial plan. Understand the impact different expected investment returns
More informationLife Fund September 2018
Life Fund September 2018 Aviva Life AXA Framlington Biotech AL / PSB This factsheet provides factual information only. The information shown should not be used in isolation for making buying and selling
More informationBasic Option Strategies
Page 1 of 9 Basic Option Strategies This chapter considers trading strategies for profiting from our ability to conduct a fundamental and technical analysis of a stock by extending our MCD example. In
More informationThe following is an extract from the April 07 Issue of The Global Speculator sent to subscribers on the 4 th of May 2007.
TECHNICALLY SOUND The following is an extract from the April 07 Issue of The Global Speculator sent to subscribers on the 4 th of May 2007. The month of April 07 has seen further falls in the US dollar
More informationSECTOR PERFORMANCE REVIEW
SECTOR PERFORMANCE REVIEW Healthcare MELISSA CAMERON & WADE ROERSON A. Sector Performance Review A-1 Sector HC Review Period Start Date 1/12/2015 End Date 4/13/2015 Ticker Recommend CIF Current Beg. Stop-loss
More informationTRADING ADDICTS. Lesson 3: Timing and Technical Indicators. Timing the Market. Copyright 2010, Trading Addicts, LLC. All Rights Reserved
Lesson 3: Timing and Technical Indicators In this chapter, we will be focusing on the timing of the trade, from each individual angle. Timing plays a critical role in a Covered Call strategy, as it can
More informationFranklin Biotechnology Discovery Fund Advisor Class
Franklin Discovery Fund Advisor Class Equity Product Profile Product Details 1 Fund Assets $1,391,510,431.86 Fund Inception Date 09/15/1997 Number of Issuers 91 NASDAQ Symbol FTDZX Maximum Sales Charge
More informationHistorical Stock Market Analysis
Historical Stock Market Analysis July 7, 2015 by Eric Bush of GaveKal Capital Before we dive into an in-depth historical stock market analysis, let s get a few data and definition questions out of the
More informationHow Much Should We Invest in Emerging Markets?
How Much Should We Invest in Emerging Markets? May 28, 2015 by Dr. Burton Malkiel of WaveFront Capital Management Investors today are significantly underexposed to emerging markets; fortunately, the opportunity
More informationThe Long-Term Bond Market Bull
McVite Equity Group Newsletter 1 st Quarter Singapore, January 30, 2018 The Long-Term Bond Market Bull Bulls believe the bond trend is still up, but evidence suggests otherwise. Rising confidence and improving
More informationCIF Stock Recommendation Report (Spring 2013)
Date: 4/08/2013 Analyst Name: Frank McLaughlin CIF Stock Recommendation Report (Spring 2013) Section (A) Summary Company Name and Ticker: Monsanto Co. (MON) Recommendation Buy: Yes Target Price: $115 Sector:
More informationTRADING ADDICTS. Lesson 2: Stock and Option Selection. Selecting a Stock. Copyright 2010, Trading Addicts, LLC. All Rights Reserved
Lesson 2: Stock and Option Selection In this chapter, we will be focusing on the process of selecting a stock. The most important part of any Covered Call strategy will be the underlying stock you choose
More informationGundlach s Forecast for 2016
Gundlach s Forecast for 2016 January 19, 2016 by Robert Huebscher Jeffrey Gundlach is a prescient and accurate forecaster. Last week, as he does each January, he offered his market outlook. But unlike
More informationMonthly Investment Compass Charting The Course Of The Markets
Monthly Investment Compass Charting The Course Of The Markets November 11 th, 2017 Monthly Investment Compass 1) Executive Summary: November 11 th, 2017 U.S. Stock Market: Unmet upside targets in several
More informationKISS. Below are a few charts which reflect that what is is not reflecting what should be. We can shout as loudly as we like but facts are facts.
KISS One reason that charts are important is that they facilitate a view of the financial world that enables one to cut through all the background waffle. Fundamental analysis anticipates what should be.
More informationThe Market. The new highs on Nasdaq were also disappointing with only 36 new highs vs. 57 just yesterday.
Page 1 Page 3 Page 6 Page 7 Page 8 The Market: More Upside at Week's End New Ideas: VOD, NUGT, IBM Updates: GOOG, BIDU, CLF, CRUS, LINKD Today s Indicator Reader Feedback & Questions: CNK, CRM, EA The
More informationMisdiagnosing The Risk Of Margin Debt
Misdiagnosing The Risk Of Margin Debt December 3, 2018 by Lance Roberts of Real Investment Advice This past week, Mark Hulbert wrote an article discussing the recent drop in margin debt. To wit: Plunging
More informationThe Bond Landscape. Thomas Denkenberger
The Bond Landscape Thomas Denkenberger In a recent interview on Bloomberg TV, former Federal Reserve Chairman Alan Greenspan remarked, "I think there are two bubbles. We have a stock market bubble and
More informationIntermediate-a? SPX2533
Summary Like last week, also this week s Friday-price action left a lot to be desired for the Bulls and ambiguity regarding which exact Elliot Wave price pattern remains: major-4 still underway? Major-4
More informationInvestors Global Health Care Class
Interim Management Report of Fund Performance FOR THE SIX-MONTH PERIOD ENDED SEPTEMBER 3, 17 CAUTION REGARDING FORWARD-LOOKING STATEMENTS This report may contain forward-looking statements about the Fund,
More informationWill The Equity Markets Become Unglued Again & What Lies Ahead For ? Presentation Delivered on November 1, 2018 by Geoff Garbacz
Will The Equity Markets Become Unglued Again & What Lies Ahead For 2018 19? Presentation Delivered on November 1, 2018 by Geoff Garbacz YTD Returns YTD Returns S&P 500 1997 to 2018 S&P 500 2013 to 2018
More informationMarket Observations - as of Jul 27, 2018
Market Observations - as of Jul 27, 2018 By Carl Jorgensen - For Objective Traders - For educational purposes only. Not Financial Advice. This week began with most markets continuing their bullish trends
More informationJefferies Healthcare Temperature Check
Jefferies Healthcare Temperature Check Diagnostics Biotechnology Consumer Health Pharmaceutical Services Medical Technology Pharmaceuticals Healthcare Services Healthcare IT Genetics This research was
More informationKEY OPTIONS. Strategy Guide
KEY OPTIONS Strategy Guide 1 Covered Call (Buy-Write) Construction buy 100 shares of stock, sell (or write) one call option. By selling the call, you ll receive immediate cash but have the potential obligation
More informationWTI Crude Oil ($WTIC)
1 WTI Crude Oil ($WTIC) Monthly While gold is giving us mixed signals, Crude Oil is not (which actually could help in analyzing gold, assuming that Crude Oil and Gold share the same fate and are correlated
More informationInvest In Asia, Health Care To Reduce Your Correlation To Oil
Invest In Asia, Health Care To Reduce Your Correlation To Oil April 19, 2016 by Eric Bush of GaveKal Capital We have written about the historically high current correlation between oil prices and stock
More informationStock Forecast Toolbox
Stock Forecast Toolbox An institutional-grade tool for the self-directed trader Overview The Stock Forecast Toolbox is at the core of our research platform. This toolset delivers highly accurate forecasts
More informationThe hypothetical bear case for biotech
ISI INTERNATIONAL STRATEGY & INVESTMENT GROUP, LLC Healthcare Research: Biotechnology & Pharmaceuticals mschoenebaum@isigrp.com W 212-446-9493 C 646-258-8128 The hypothetical bear case for biotech Being
More informationcovered warrants uncovered an explanation and the applications of covered warrants
covered warrants uncovered an explanation and the applications of covered warrants Disclaimer Whilst all reasonable care has been taken to ensure the accuracy of the information comprising this brochure,
More informationStocks, Bonds, U.S. Dollar Index, Precious Metals and Special Opportunities Updated Every Monday, Wednesday and Friday (except U.S.
Stocks, Bonds, U.S. Dollar Index, Precious Metals and Special Opportunities Updated Every Monday, Wednesday and Friday (except U.S. Holidays) The SM is service marked and copyrighted by Elliott Wave International
More informationIMPORTANT INFORMATION REGARDING YOUR HOLDRS TRUST INVESTMENT:
IMPORTANT INFORMATION REGARDING YOUR HOLDRS TRUST INVESTMENT: Van Eck Global presents an exchange offer from its Market Vectors ETF Trust. Van Eck is offering investors of certain HOLDRS Trusts the opportunity
More informationCIF Sector Recommendation Report (Spring 2013)
Date: 4/22/13 Analyst: Walter Nabarrete CIF Sector Recommendation Report (Spring 2013) Sector Materials Review Period 4/5 to 4/19 Section (A) Sector Performance Review MAT Ticker Current Beg. Stop-loss
More informationWeekly outlook for Jan. 28 Feb
Weekly outlook for Jan. 28 Feb. 1 2019 Summary The S&P500 index is expected to continue its rally, but there is a lot of economic data due this week and a n abundance of external news events. All of this
More informationS&P 500 Update: Week ending May 11th 2018
S&P 500 Update: Week ending May 11th 2018 1. Market Recap: The S&P 500 closed higher by 2.2% for week and broke out of some key resistance areas and a short term downtrend. There are 4 topics now setting
More informationMorning Client Note Wednesday, September 17, 2014
Morning Client Note Wednesday, September 17, 2014 DOW Futures (RR) $17,035 and head higher to fixed targeted-resistance at $17,100. The overnight low was $17,036 and the overnight high was $17,064. Price
More informationUS Financial Market Chart Book for February/March February 23, 2012
US Financial Market Chart Book for February/March 2012 February 23, 2012 US Financial Market Chart Book Executive Summary: February 23 rd 2012 U.S. Stocks: The benchmark S&P 500 and bellwether Dow Jones
More informationDescription. Frequency. Strength
Introduction The core of Jim Fink s Options for Income trading service are vertical put credit spreads of 1-4 months in duration, where the objective is for the underlying stock price to close at options
More informationPowered by Artificial Intelligence OUT
Powered by Artificial Intelligence SUMMARY OF CHANGES IN OUT Snap Inc Macy s Inc Cisco Systems Inc Mattel Inc Wells Fargo & Co Western Digital Corp Chipotle Mexican Grill Inc Under Armour Inc General Motors
More informationToday's Overview. I took a nice piece out of the Phillip Morris (PM) bounce but chose not to hold the position overnight. I cannot wait for September.
Today's Overview Sellers remained in control overnight, with risk adversity growing in response to a flood of European sound bites about the fate of Greece and European Central Bank bond buying. The euro
More informationThe Nitty-Gritty of Currency Hedged Bonds
The Nitty-Gritty of Currency Hedged Bonds September 15, 2016 by Eric Bush of GaveKal Capital If you are like us and try to read as much economic research and market commentary as you can, you have probably
More informationMarket Price Considerations Week Beginning December 26, 2016
Market Price Considerations Week Beginning December 26, 2016 DISCLAIMER-FOR-EDUCATIONAL-PURPOSES-ONLY Bobby Coats, Ph.D. Professor Economics Department of Agricultural Economics and Agribusiness Division
More informationPowered by Artificial Intelligence OUT
Powered by Artificial Intelligence SUMMARY OF CHANGES IN OUT Square Inc Valeant Pharmaceuticals Intern Kite Pharma Inc Target Corp Oracle Corp Ionis Pharmaceuticals Inc Blackstone Group LP/The Lam Research
More informationTechnical Analysis for Options Trading. Fidelity Brokerage Services LLC, Member NYSE, SIPC, 900 Salem Street, Smithfield, RI
Technical Analysis for Options Trading Fidelity Brokerage Services LLC, Member NYSE, SIPC, 900 Salem Street, Smithfield, RI 02917 747561.2.0 Disclosures Options trading entails significant risk and is
More informationMarket Observations - as of May 11, 2018
Market Observations - as of May 11, 2018 By Carl Jorgensen - For Objective Traders - For educational purposes only. Not Financial Advice. After about four weeks of very little net change in the major indexes
More informationThis would lower the year-end S&P 500 target price from 2,140 to 2,040. The technical picture of the market is also deteriorating.
January 13, 2016 SPECIAL BULLETIN We are now in the 82 nd month of a Bull Market and U.S. Markets are now getting very close to giving a SELL SIGNAL. As you know, I have been bullish on the market since
More informationHow the US Economy Has Been Affected by a Weakening Yuan
How the US Economy Has Been Affected by a Weakening Yuan September 12, 2016 by Eric Bush of GaveKal Capital Earlier this week we blogged about how the most important stat in the monthly employment report,
More informationIn the Wake of the Downgrade, New Opportunities
141 W. Jackson Boulevard Suite 4002 Chicago, IL 60604 312.786.4450 / 800.662.9346 Part of the market s malaise since August 1st came as a result of bickering in Washington over whether to raise the US
More informationRESUMPTION OF THE GENERATIONAL GOLD BULL MARKET?
RESUMPTION OF THE GENERATIONAL GOLD BULL MARKET? These past weeks, Gold broke out to the upside after a 4 year correction. I waited until today for confirmation on the monthly chart that this breakout
More informationThackray Sector Report
Thackray Sector Report Every Sector has a Season May 29, 2018 Written by Brooke Thackray GOVERNMENT BONDS... Hated by most investors... Government bonds could provide value ahead? The decline in the 10-year
More informationHow to perform accurate market analysis
How to perform accurate market Roman Sadowski Good market combines the fundamental and the technical. This combination is essential to form a longer-term bias in the market. Good market needs to consider
More informationTrade NFP based on historical Correlation
Today we are waiting the big US data to be released NFP (Non-Farm-Payroll); Which markets do expect that the economy successfully will add 210,000 to 216,000 jobs and the unemployment rate would fall to
More informationMorning Trading Comments
Wednesday, June 13, 2018 1 Morning Trading Comments SUMMARY OF TRADING VIEWS The S&P 500 index is now close to the 2800 area, a potential important resistance zone. It will be interesting to see how this
More informationPlan of Attack... Page 2 ETF Watch... Page 4 Model Portfolio... Page 8
TABLE OF CONTENTS Market Background... Page 1 Plan of Attack... Page 2 ETF Watch... Page 4 Model Portfolio... Page 8 Market Background After a short holiday week that was much more difficult to navigate
More informationthe Flight to Equities Continues
the Flight to Equities Continues By Gerry Hansell, Jeff Kotzen, Frank Plaschke, Eric Olsen, and Hady Farag This is the first in a series of articles published as part of The Boston Consulting Group s 24
More information